Article

Development and pharmacological characterization of a rat model of osteoarthritis pain

Purdue Pharma L.P., Stamford, Connecticut, United States
Pain (Impact Factor: 5.84). 05/2005; 114(3):339-46. DOI: 10.1016/j.pain.2004.11.008
Source: PubMed

ABSTRACT Osteoarthritis (OA) is an age-related joint disease characterized by degeneration of articular cartilage and is associated with chronic pain. Although several experimental models of OA have been employed to investigate the underlying etiologies of the disease, there has been relatively little investigation into development of animal models of OA to study the pain associated with the condition. In the present study, we investigated OA induced by injection of either iodoacetate or papain into the knee joint of rats, and assessed the joint degeneration with radiographic analyses and measured pain behavior using hind limb weight bearing. We found that injection of iodoacetate, but not papain, resulted in a chronic joint degeneration as measured by decreased bone mineral content and bone mineral density, necrosis of articular cartilage and osteophyte formation. These pathological changes were associated with pain that manifested as time- and concentration-dependent alterations in hind limb weight bearing. These alterations in hind limb weight bearing were reversed with morphine, but were not significantly affected by acute administration of either indomethacin or celecoxib. However, administration of 30 mg/kg celecoxib twice daily for 10 days resulted in a significant restoration of hind limb weight bearing. We conclude that the iodoacetate model of OA is a relevant animal model to study pain associated with OA, and can be used to test potential therapeutic agents.

Full-text

Available from: James D Pomonis, Sep 17, 2014
1 Follower
 · 
81 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The pharmacological inhibition of anandamide (AEA) hydrolysis by fatty acid amide hydrolase (FAAH) attenuates pain in animal models of osteoarthritis but has failed in clinical trials. This may have occurred because AEA also activates transient receptor potential vanilloid type-1 (TRPV1), which contributes to pain development. Therefore, we investigated the effectiveness of the dual FAAH-TRPV1 blocker OMDM-198 in an MIA-model of osteoarthritic pain. We first investigated the MIA-induced model of osteoarthritis by 1) characterizing the pain phenotype and degenerative changes within the joint using X-ray microtomography and 2) evaluating nerve injury and inflammation marker (ATF-3 and IL-6) expression in the lumbar DRG of osteoarthritic rats and differences in gene and protein expression of the cannabinoid CB1 receptors FAAH and TRPV1. Furthermore, we compared OMDM-198 with compounds acting exclusively on FAAH or TRPV1. Osteoarthritis was accompanied by the fragmentation of bone microstructure and destroyed cartilage. An increase of the mRNA levels of ATF3 and IL-6 and an upregulation of AEA receptors and FAAH in the DRG was observed. OMDM-198 showed anti-hyperalgesic effects in the osteoarthritis model, which were comparable to those of a selective TRPV1 antagonist, SB-366,791, and a selective FAAH inhibitor, URB-597. The effect of OMDM-198 was attenuated by the CB1 receptor antagonist, AM-251, and by the non-pungent TRPV1 agonist, olvanil, suggesting its action as an "indirect" CB1 agonist and TRPV1 antagonist. These results suggest an innovative strategy for the treatment of osteoarthritis, which may yield more satisfactory results than those obtained so far with selective FAAH inhibitors in human osteoarthritis.
    Pain 02/2015; 156(5). DOI:10.1097/j.pain.0000000000000132 · 5.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Voltage gated sodium channel blockers are not traditionally recommended for osteoarthritis (OA) pain therapy, but given the large peripheral drive that follows OA development there is a rationale for their use. Using a rat model of monosodium iodoacetate (MIA) induced osteoarthritis we used in vivo electrophysiology to assess the effects of the Nav1.7 and Nav 1.8 selective antagonists, ProTxII and A-803467 respectively, on the evoked activity of spinal dorsal horn neurons in response to electrical, mechanical and thermal stimuli applied to the peripheral receptive field. These studies allow examination of the roles of these channels in suprathreshold stimuli, not amenable to behavioural threshold measures. Spinal administration of ProTxII significantly reduced neuronal responses evoked by mechanical punctate (von Frey (vF) 8- 60g) and noxious thermal (45 and 48 (0)C) stimuli in MIA rats only. A-803467 significantly inhibited neuronal responses evoked by vF 8 - 60g and 48(0)C heat after spinal administration; significantly inhibited responses evoked by brush, vFs 26-60g and 40- 48(0)C stimuli after systemic administration; significantly inhibited the electrically evoked Aδ-, C-fiber, post-discharge, Input and wind-up responses and the brush, vFs 8- 60g and 45 - 48(0)C evoked neuronal responses after intra plantar injection in the MIA group. In comparison A-803467 effects in the sham group were minimal and included a reduction of the neuronal response evoked by vF60g and 45(0)C heat stimulation after spinal administration, no effect after systemic administration and an inhibition of the evoked response to 45(0)C heat after intra plantar injection only. The observed selective inhibitory effect of ProTxII and A-803467 for the MIA treated group suggest an increased role of Nav 1.7 and 1.8 within nociceptive pathways in the arthritic condition, located at peripheral and central sites. These findings demonstrate the importance of, and add to, the mechanistic understanding of these channels in osteoarthritic pain. Copyright © 2015. Published by Elsevier Ltd.
    Neuroscience 03/2015; 15. DOI:10.1016/j.neuroscience.2015.03.042 · 3.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionAlterations in voltage gated sodium channel (VGSC) function have been linked to chronic pain and are good targets for analgesics. Lacosamide (LCM) is a novel anticonvulsant that enhances the slow inactivation state of VGSCs. This conformational state can be induced by repeated neuronal firing and/or under conditions of sustained membrane depolarisation; as is expected for hyperexcitable neurones in pathological conditions such as epilepsy and neuropathy, and probably osteoarthritis (OA). This study, therefore, examined the antinociceptive effect of LCM on spinal neuronal and behavioural measures of pain, in vivo, in a rat OA model.MethodsOA was induced in Sprague Dawley rats by intra-articular injection of 2mg monosodium iodoacetate (MIA). Shams were injected with saline. Behavioural responses to mechanical and cooling stimulation of the ipsilateral hind paw and hind-limb weight bearing were recorded. In vivo electrophysiology was performed in anaesthetised MIA or sham rats, recording the effects of spinal or systemic administration of LCM on the evoked responses of dorsal horn neurones to electrical, mechanical (brush, von Frey (vF) 2-60g) and heat (40-50°C) stimulation of the peripheral receptive field. The effect of systemic LCM on nociceptive behaviours was assessed.ResultsBehavioural hypersensitivity, ipsilateral to knee injury, was seen as a reduced paw withdrawal threshold to mechanical stimulation, an increase in paw withdrawal frequency to cooling stimulation and hind-limb weight bearing asymmetry in MIA rats only. Spinal and systemic administration of LCM produced significant reductions of the electrical Aß- and C-fiber evoked neuronal responses and the mechanical and thermal evoked neuronal responses in the MIA group only. Systemic administration of LCM significantly reversed the behavioural hypersensitive responses to mechanical and cooling stimulation of the ipsilateral hind paw, but hind limb weight bearing asymmetry was not corrected.Conclusions Our in vivo electrophysiological results show that the inhibitory effects of LCM were MIA dependent. This suggests that if used in OA patients, LCM may allow physiological transmission yet suppress secondary hyperlagesia and allodynia. The inhibitory effect on spinal neuronal firing aligned with analgesic efficacy on nociceptive behaviours and suggests that LCM may still prove worthwhile for OA pain treatment and merits further clinical investigation.
    Arthritis Research & Therapy 12/2014; 16(6):509. DOI:10.1186/s13075-014-0509-x · 4.12 Impact Factor